Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Mitchell, E. P.
Lacouture, M.
Shearer, H.
Iannotti, N.
Piperdi, B.
Pillai, M.
Xu, F.
Yassine, M.
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] Piedmont Hematol Oncol Associates PLLC, Winston Salem, NC USA
[4] Hematol Oncol Associates Treasure Coast, Port St Lucie, FL USA
[5] Univ Massachusetts, Med Ctr, Worcester, MA USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4027
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP
    Kobayashi, Yoshimitsu
    Komatsu, Yoshito
    Yuki, Satoshi
    Fukushima, Hiraku
    Sasaki, Takahide
    Iwanaga, Ichiro
    Uebayashi, Minoru
    Okuda, Hiroyuki
    Kusumi, Takaya
    Miyagishima, Takuto
    Sogabe, Susumu
    Tateyama, Miki
    Hatanaka, Kazuteru
    Tsuji, Yasushi
    Nakamura, Michio
    Konno, Jun
    Yamamoto, Fumiyasu
    Onodera, Manabu
    Iwai, Kazuhiro
    Sakata, Yuh
    Abe, Riichiro
    Oba, Koji
    Sakamoto, Naoya
    FUTURE ONCOLOGY, 2015, 11 (04) : 617 - 627
  • [42] Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data
    Siena, S.
    Tabernero, J.
    Burkes, R. L.
    Cassidy, J.
    Cunningham, D.
    Barugel, M. E.
    Humblet, Y.
    McPhie, C.
    Shing, M.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
    Tubb, E. E.
    Nugent, M.
    Spielberger, J.
    Axelrod, R. A.
    Mitchell, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] SPIRITT (STUDY 20060141): A RANDOMISED PHASE 2 STUDY OF FOLFIRI WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 2ND-LINE TREATMENT (tx) IN PATIENTS (pts) WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)
    Hecht, J. R.
    Cohn, A.
    Dakhil, S.
    Saleh, M.
    Cline-Burkhardt, M.
    Piperdi, B.
    Tian, Y.
    Go, W.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 56 - 56
  • [45] A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results.
    Van Cutsem, E.
    Eng, C.
    Tabernero, J.
    Nowara, E.
    Swieboda-Sadlej, A.
    Tebbutt, N. C.
    Mitchell, E. P.
    Davidenko, I.
    Chen, L.
    Smethurst, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [46] Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials
    Berlin, J.
    Van Cutsem, E.
    Peeters, M.
    Hecht, J. R.
    Ruiz, R.
    Wolf, M.
    Amado, R. G.
    Meropol, N. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Final results of a pharmacokinetic (PK) study of capecitabine (X) in combination with oxaliplatin (0) for patients (pts) with metastatic colorectal cancer (MCRC).
    Gil-Delgad, M
    Bastian, G
    Paule, B
    Spano, JP
    Rixe, O
    Guetz, GD
    Urien, S
    Amaury-Soares, J
    Breau, JL
    Castaing, D
    Khayat, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 292S - 292S
  • [48] Quality of life (QoL) during second-line treatment with FOLFIRI plus /- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC)
    Sobrero, A. F.
    Price, T. J.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Lordick, F.
    Punt, C. J.
    Hechmati, G.
    Demonty, G.
    Koukakis, R.
    Peeters, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S369 - S370
  • [49] Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6+either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)
    Rivera, F.
    Karthaus, M.
    Hecht, J. R.
    Fasola, G.
    Canon, J. L.
    Guan, X.
    Demonty, G.
    Schwartzberg, L. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S332 - S333
  • [50] Epidermal growth factor receptor (EGFR) inhibitor-related skin toxicity: Review of interim data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC)
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Gamelin, E.
    Wright, L.
    Kohne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345